Abstracts tagged "axial spondyloarthritis"

Abstract Number: 748 • 2019 ACR/ARP Annual Meeting
Takayasu Arteritis and Sacroiliitis: A Case Control Study in 28 Patients of a Single Italian Center
Paola Toniati¹, Francesca Regola ¹, Franco Franceschini ¹, Giovanni Bosio ² and Angela Tincani ³, ¹Rheumatology and Clinical Immunology Unit, ASST Spedali Civili and University of Brescia, Brescia, Italy, Brescia, Italy, ²Nuclear Medicine Unit, ASST Spedali Civili of Brescia, Brescia, Italy, Brescia, Italy, ³Rheumatology and Clinical Immunology, Spedali Civili and Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy, Brescia, Italy
Background/Purpose: A lot of clinical case descriptions about spondyloarthropathy in TAK patients were reported. Recently, a paper about an increased incidence of spondyloarthropathy in TAK…
Abstract Number: 1482 • 2019 ACR/ARP Annual Meeting
Secukinumab Provides Sustained Improvement of Enthesitis in Ankylosing Spondylitis Patients: A Pooled Analysis of Four Pivotal Phase 3 Trials
Georg Schett¹, Xenofon Baraliakos ², Filip Van den Bosch ³, Atul Deodhar ⁴, Lianne Gensler ⁵, Mikkel Østergaard ⁶, Shital Agawane ⁷, Ayan Das Gupta ⁷, Shephard Mpofu ⁸, Todd Fox ⁸, Adam Winseck ⁹, Brian Porter ⁹ and Abhijit Shete ⁸, ¹Department of Internal Medicine 3, Friedrich Alexander University Erlangen-Nuremberg, Erlangen, Germany, ²Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ³Ghent University Hospital, Ghent, Belgium, ⁴Oregon Health & Science University, Portland, OR, ⁵University San Francisco California, San Francisco, CA, ⁶Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark, ⁷Novartis Healthcare Pvt Ltd, Hyderabad, India, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: Enthesitis can be a debilitating spondyloarthritis (SpA) manifestation and the cause of pain, reduced quality of life and impaired physical function.1,2 Herein, we evaluated…
Abstract Number: 1547 • 2019 ACR/ARP Annual Meeting
Ixekizumab Improves Self-reported Overall Functioning and Health as Measured by the Assessment of SpondyloArthritis International Society Health Index in Patients with Active Radiographic Axial Spondyloarthritis: 52-Week Results of Two Phase 3 Randomized Trials
Uta Kiltz¹, Désirée van der Heijde ², Annelies Boonen ³, Lianne Gensler ⁴, Theresa Hunter ⁵, Fangyi Zhao ⁶, Baojin Zhu ⁵, Rebecca Bolce ⁵, Hilde Carlier ⁵ and Jürgen Braun ⁷, ¹Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, ²Leiden University Medical Center, Leiden, Netherlands, ³Maastricht University Medical Center, Maastricht, Netherlands, ⁴University San Francisco California, San Francisco, CA, ⁵Eli Lilly and Company, Indianapolis, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany
Background/Purpose: The Assessment of SpondyloArthritis international Society Health Index (ASAS HI) measures health, disability, and functioning in patients (pts) with spondyloarthritis (SpA)[1,2]. The purpose of…
Abstract Number: 2776 • 2019 ACR/ARP Annual Meeting
5-years Treatment Effect of TNF Alpha Inhibitor in Early Axial Spondyloarthritis and Associated Factors: An Inverse Probability Weighting Analysis of the DESIR Cohort
Marion Pons ¹, Sylvie Chevret ², Karine Briot ¹, Maria-Antonietta D’Agostino ³, Christian Roux ⁴, Maxime Dougados ⁵ and Anna Moltó⁴, ¹Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, ²INSERM U-1153, CRESS Paris-Sorbonne, Paris, Paris, Ile-de-France, France, ³Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, ⁴Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁵Cochin Hospital, Paris, France
Background/Purpose: Only scarce date is available on the long term treatment effect in a real-life setting (i.e. effectiveness) of TNFi in early axial SpA forms…
Abstract Number: 567 • 2019 ACR/ARP Annual Meeting
Worse Outcomes for Female Patients with Axial Spondyloarthropathy
Sinead Maguire¹, Gillian Fitzgerald ², Claire Sheehy ³ and Finbar O'Shea ², ¹University Hospital Waterford, Dublin, Ireland, ²St James' Hospital, Dublin, Ireland, ³University Hospital Waterford, Waterford, Ireland
Background/Purpose: Axial Spondyloarthritis(axSpA) is known to have a male predominance. There is little available literature examining affected female patients. Previous studies have included small numbers…
Abstract Number: 604 • 2019 ACR/ARP Annual Meeting
Do Illness Perceptions and Coping Change over Time in Patients Recently Diagnosed with Axial Spondyloarthritis? A 2-Year Follow-Up Study in the SPACE Cohort
Miranda van Lunteren¹, Robert B.M. Landewé ², Camilla Fongen ³, Roberta Ramonda ⁴, Désirée van der Heijde ¹ and Floris van Gaalen ¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Amsterdam University Medical Center, Amsterdam, Netherlands, ³Diakonhjemmet Hospital, Oslo, Norway, ⁴University of Padova, Padova, Italy
Background/Purpose: We have previously shown that in patients with recently diagnosed axial SpA (axSpA), illness perceptions had a negative impact on the relationship between back…
Abstract Number: 837 • 2019 ACR/ARP Annual Meeting
Does Discordance Between Baseline Patient’s and Evaluator’s Global Assessment of Disease Activity Impact Retention and Remission Rates of a First TNF Inhibitor in Patients with Axial Spondyloarthritis? Data from the EuroSpA Research Collaboration Network
Brigitte Michelsen¹, Lykke Midtbøll Ørnbjerg ², Anne Gitte Loft ³, Tore Kvien ⁴, Adrian Ciurea ⁵, Herman Mann ⁶, Kari K. Eklund ⁷, Ayten Yazici ⁸, Maria José Santos ⁹, Johan Askling ¹⁰, Ziga Rotar ¹¹, Bjorn Gudbjornsson ¹², Manuel Pombo-Suarez ¹³, Catalin Codreanu ¹⁴, Irene van der Horst-Bruinsma ¹⁵, Eirik Kristianslund ¹⁶, Michael J. Nissen ¹⁷, Karel Pavelka ⁶, Nina Trokovic ¹⁸, Nevsun Inanc ¹⁹, Elsa Vieira-Sousa ²⁰, Daniela DiGuiseppe ²¹, Matija Tomsic ²², Arni Jon Geirsson ²³, Ruxandra IONESCU ²⁴, Marleen van de Sande ²⁵, Florenzo Iannone ²⁶, Carlos Sánchez-Piedra ²⁷, Gareth Jones ²⁸, Lise Hyldstrup ², Merete Lund Hetland ²⁹ and Mikkel Østergaard ³⁰, ¹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark/ Hospital of Southern Norway Trust, Kristiansand, Norway/ Diakonhjemmet Hospital, Oslo, Norway, Oslo, Norway, ²Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet Glostrup, Denmark, Copenhagen, Denmark, ³Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark, Århus, Denmark, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵University Hospital Zürich, Zürich, Switzerland, ⁶Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Prague, Czech Republic, Prague 2, Czech Republic, ⁷ROB-FIN registry, Department of Medicine, Helsinki University and University Hospital, Helsinki, Finland, ⁸Kocaeli University, Faculty of Medicine, Division of Rheumatology, Kocaeli, Kocaeli, Turkey, ⁹Rheumatology department, Hospital Garcia de Orta, Almada, Portugal, ¹⁰Karolinska Institutet, Stockholm, Sweden, ¹¹UMC LJUBLJANA, DPT. OF RHEUMATOLOGY, LJUBLJANA, Slovenia, ¹²Centre for Rheumatology Research, Landspitali and Faculty of Medicine, University of Iceland, Reykjavik, Iceland, ¹³Unit Research, Spanish Society of Rheumatology, Madrid, Spain, ¹⁴Center of Rheumatic Diseases, University of Medicine and Pharmacy, Bucharest, Romania., Bucharest, Romania, ¹⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ¹⁶Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway., Oslo, Norway, ¹⁷University Hospital Geneva, Geneva, Switzerland, ¹⁸Helsinki University Central Hospital, Helsinki, Finland, ¹⁹Marmara University, Faculty of Medicine, Division of Rheumatology, Istanbul, Turkey, ISTANBUL, Turkey, ²⁰Rheumatology and Metabolic Bone Diseases, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, EPE | Rheumatology Research Unit, Instituto de Medicina Molecular - Faculty of Medicine, University of Lisbon, Lisbon Academic Medical Centre, Lisbon, Portugal,, Lisbon, Portugal, ²¹Clinical Epidemiology Division, Dept of Medicine Solna, Karolinska Institutet,, Stockholm, Sweden, ²²Department of Rheumatology, University Medical Center Ljubljana, Slovenia, Ljubljana, Slovenia, ²³Centre for Rheumatology Research, University Hospital and Faculty of Medicine, Reykjavik, Iceland, ²⁴SPITALUL CLINIC SFANTA MARIA, Bucharest, ²⁵Amsterdam UMC, Amsterdam, Netherlands, ²⁶Department of Emergency and Transplantation , Rheumatology Unit, University Hospital of Bari, Bari, Italy., Bari, Italy, ²⁷Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ²⁸University of Aberdeen, Aberdeen, United Kingdom, ²⁹DANBIO and Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Rigshospitalet, Copenhagen, Denmark, ³⁰Copenhagen Center for Arthritis Research, University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Discordance between baseline patient’s and evaluator’s global assessment of disease activity is common.1 However, the impact of such discordance on retention and remission rates…
Abstract Number: 1487 • 2019 ACR/ARP Annual Meeting
Impact of TNF-α Inhibitor on Lipid Profile and Atherogenic Index of Plasma in Axial Spondyloarthritis: Two-year Follow-up Data from the Catholic Axial Spondyloarthritis COhort (CASCO)
Hong Ki Min¹, Seung-Ki Kwok ² and Sang-Heon Lee ¹, ¹Konkuk university medical center, Seoul, Republic of Korea, ²Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea
Background/Purpose: To evaluate the influence of TNF-α inhibitor on lipid profile and atherogenic index of plasma (AIP) in axial spondyloarthritis (axSpA) patients with long term…
Abstract Number: 1548 • 2019 ACR/ARP Annual Meeting
Drug Survival of Secukinumab for Axial Spondyloarthritis in a Real-World Setting Possible Response Factors
Carolina Merino Argumanez¹, Valentina Emperiale ², María Martín ³, Marta Valero ⁴, javier Bachiller ⁵, Beatriz Joven-Ibáñez ⁶, Ana Pérez-Gómez ⁷ and Jose Campos ¹, ¹Hospital Universitario Puerta de Hierro, Majadahonda (Madrid), Spain, ²Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Spain, ³Hospital Universitario Doce de Octubre, Madrid, Spain, ⁴Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Rheumatology Department, Ramón y Cajal University Hospital & IRYCIS, Madrid, Spain, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Hospital Universitario Príncipe de Asturias, Alcalá de Henares, Madrid, Spain
Background/Purpose: Secukinumab is a newly introduced biologic therapy against IL-17 which has been proved effective in patients with ankylosing spondylitis (AS) in clinical trials and…
Abstract Number: 2777 • 2019 ACR/ARP Annual Meeting
What Is Axial Spondyloarthritis? A Latent Class and Transition Analysis in the SPACE and DESIR Cohorts
Alexandre Sepriano¹, Sofia Ramiro ², Désirée van der Heijde ¹, Pierre Hoonhout ³, Anna Moltó ⁴, Alain Saraux ⁵, Maxime Dougados ⁶ and Robert B.M. Landewé ⁷, ¹Leiden University Medical Center, Leiden, Netherlands, ²Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ³ISEG - Lisbon School of Economics and Management, Lisbon, Portugal, ⁴Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁵CHU de la Cavale-Blanche Brest, Brest, France, ⁶Cochin Hospital, Paris, France, ⁷Amsterdam University Medical Center, Amsterdam, Netherlands
Background/Purpose: Axial spondyloarthritis (axSpA) is a disease with a rather heterogeneous presentation that may be difficult to diagnose. Classification criteria, such as the ASAS criteria,…
Abstract Number: 568 • 2019 ACR/ARP Annual Meeting
Understanding mNY Radiograph Score Discordance in Axial Spondyloarthritis Clinical Trials Using Imaging Criteria for Subject Eligibility
Farhan Syed¹, Kassel Fotinos-Hoyer ², Michael O'Connor ³, Maureen Li ³, Bryan Hermannsson ², Nicholas Enus ³, Sayali Karve ³, Manish Sharma ⁴, Gabriele Pradella ³, Robert B.M. Landewé ⁵, Xenofon Baraliakos ⁶ and Sarah Warner ³, ¹Parexel, Billerica, MA, ²Parexel, Berlin, Germany, ³Parexel, Billerica, ⁴Parexel, Hyderabad, India, ⁵Amsterdam University Medical Center, Amsterdam, Netherlands, ⁶Rheumatology Department, Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Bochum, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is typically radiographically confirmed on the sacroiliac joint (SIJ) as assessed by the modified New York (mNY) criteria. In clinical trials,…
Abstract Number: 606 • 2019 ACR/ARP Annual Meeting
Effectiveness of TNFi After a First Switch in Patients with Early Axial Spondyloarthritis: A Longitudinal Analysis of the DESIR Cohort
Marion Pons ¹, Sylvie Chevret ², Karine Briot ³, Maria-Antonietta D’Agostino ⁴, Christian Roux ⁵, Maxime Dougados ⁶ and Anna Moltó⁵, ¹Rheumatology department, Cochin Hospital, Paris, Paris, Ile-de-France, France, ²INSERM U-1153, CRESS Paris-Sorbonne, Paris, Paris, Ile-de-France, France, ³Rheumatology department, Cochin Hospital, Paris, France, Paris, Ile-de-France, France, ⁴Department of Rheumatology, APHP, Hôpital Ambroise Paré, Paris, France, ⁵Paris Descartes University, Cochin Hospital, Rheumatology department, Paris, France, ⁶Cochin Hospital, Paris, France
Background/Purpose: Contradictory data has been reported on the effectiveness of a second and third line of TNFi in early axial spondyloarthritis (axSpA). The objective of…
Abstract Number: 851 • 2019 ACR/ARP Annual Meeting
Association Between Bone Marrow Edema and Structural Progression in the Same Quadrant in Axial Spondyloarthritis – 5-year Data from the DESIR Cohort
Santiago Rodrigues-Manica¹, Alexandre Sepriano ², Sofia Ramiro ³, Robert B.M. Landewé ⁴, Pascal Claudepierre ⁵, Anna Molto ⁶, Maxime Dougados ⁷, Miranda van Lunteren ² and Désirée van der Heijde ², ¹CEDOC, NOVA-Medical School | Hospital Egas Moniz, CHLO, Lisbon, Lisbon, Portugal, ²Leiden University Medical Center, Leiden, Netherlands, ³Leiden University Medical Center and Zuyderland Medical Centre, Leiden, Netherlands, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Rheumatology, CHU Henri Mondor Créteil, Paris, France, ⁶Paris Descartes University, Medicine Faculty; APHP, Rheumatology, Hôpital Cochin, Hôpitaux de Paris, Paris, Paris, France, ⁷Cochin Hospital, Paris, France
Background/Purpose: The overall presence of inflammation in the MRI-SIJ is associated with overall 5-year radiographic damage in patients with axSpA. But we do not know…
Abstract Number: 1491 • 2019 ACR/ARP Annual Meeting
Long-term Clinical Outcome of Anti-TNF Treatment in Patients with Early Axial Spondyloarthritis: 10-year Data of the Etanercept vs. Sulfasalazin in Early Axial Spondyloarthritis Trial
Fabian Proft¹, Murat Torgutalp ², Anja Weiß ³, Mikhail Protopopov ⁴, Valeria Rios Rodriguez ⁵, Hildrun Haibel ¹, Olaf Behmer ⁶, Joachim Sieper ¹ and Denis Poddubnyy ⁷, ¹Charité Universitätsmedizin Berlin, Germany, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Germany and Ankara University Faculty of Medicine, Ankara, Turkey., Berlin, Germany, ³German Rheumatism Research Center (DRFZ), Berlin, Germany, ⁴Charité Universitätsmedizin Berlin, Germany, Berlin, Berlin, Germany, ⁵Charité Universitätsmedizin, Berlin, Germany, ⁶Pfizer Inc., Berlin, Germany, ⁷Charité - Universitätsmedizin Berlin and German Rheumatism Research Centre, Berlin, Germany, Berlin, Germany
Background/Purpose: Long-term data on anti-TNF treatment in patients with early axial spondyloarthritis (SpA) is scarce. The objective of this analysis was to assess the long-term…
Abstract Number: 1549 • 2019 ACR/ARP Annual Meeting
Primary 1-Year Data of Ixekizumab in Biologic Disease-Modifying Anti-rheumatic Drug-Naïve Patients with Radiographic Axial Spondyloarthritis Including Data in Patients Rerandomized from Adalimumab to Ixekizumab
Cheng-Chung Wei¹, Lianne Gensler ², Jessica Walsh ³, Robert B.M. Landewé ⁴, Tetsuya Tomita ⁵, Fangyi Zhao ⁶, Gaia Gallo ⁶, Hilde Carlier ⁷ and Maxime Dougados ⁸, ¹Chung Shan Medical University, Taichung City, Taiwan (Republic of China), ²University San Francisco California, San Francisco, CA, ³Division of Rheumatology, University of Utah, Salt Lake City, UT, ⁴Amsterdam University Medical Center, Amsterdam, Netherlands, ⁵Osaka University Graduate School of Medicine, Osaka, Japan, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly and Company, Indianapolis, ⁸Hôpital Cochin, Paris, France
Background/Purpose: During 16 weeks of blinded treatment, ixekizumab (IXE) and an adalimumab (ADA) active reference arm were found superior to placebo (PBO) in improving signs…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].